Author: Bill Snyder
Omicron evades some but not all monoclonal antibodies: study
Jan. 20, 2022—A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.
Pozzi elected president of Society for Matrix Biology
Jan. 20, 2022—Vanderbilt's Ambra Pozzi, PhD, has been elected president of the American Society for Matrix Biology (ASMB), a scientific organization that promotes research on the extracellular matrix with the aim of improving human health.
Ensuring the “best possible” medication history
Jan. 18, 2022—About 80% of hospital admission electronic records were missing a drug prescribed to an older adult, Vanderbilt researchers found, highlighting the need for a multipronged approach to address medication discrepancies and support safe prescribing practices.
The role of integrins in kidney “integrity”
Jan. 13, 2022—Receptors called integrins play a critical role in maintaining the structure of the kidney, Vanderbilt researchers have discovered.
Study seeks to refine head and neck cancer treatment options
Jan. 13, 2022— by Bill Snyder Researchers at Case Western Reserve University and Vanderbilt University Medical Center are pioneering the use of computer-aided image analysis to improve the prognostication and treatment of head and neck cancer. Each year in the United States, approximately 16,000 patients are diagnosed with a form of head-and-neck cancer called oropharyngeal squamous cell...
Nashville Biosciences and Illumina announce agreement to establish preeminent clinico-genomic resource for life sciences research & development
Jan. 10, 2022—Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center, has announced an agreement with Illumina, a leading genomic technology company, to realize the full potential of VUMC’s DNA databank, BioVU.
Study explores how bacteria become drug resistant
Jan. 6, 2022—Vanderbilt researchers have revealed more of the inner-workings of a two-stage “molecular motor” in the cell membrane that enables bacteria to become resistant to drugs.
Patient receives antibodies discovered at Vanderbilt to prevent COVID-19 illness
Dec. 23, 2021—On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19.
“Atlas” of lung development may aid efforts to heal premature lungs
Dec. 20, 2021—Researchers at Vanderbilt University Medical Center have constructed a single-cell “atlas” of lung development that tracks multiple cell types over time.
Silver appointed to national committee assessing human requirements for energy intake and expenditure
Dec. 17, 2021—Vanderbilt's Heidi Silver, PhD, RDN, MS, has been appointed to an ad hoc committee of the National Academies of Sciences, Engineering, and Medicine to assess the human requirements for energy intake and expenditure.
Two VUMC papers named among genomic medicine’s top 10
Dec. 16, 2021—Vanderbilt researchers wrote two of the “top 10” papers representing key advances in genomic medicine published between September 2020 and August 2021.
“Supermeres” may carry clues to cancer, Alzheimer’s disease and COVID-19
Dec. 10, 2021—Vanderbilt researchers have discovered a nanoparticle released from cells, called a “supermere,” which contains enzymes, proteins and RNA associated with multiple cancers, cardiovascular disease, Alzheimer’s disease and even COVID-19.
